老虎没有暗盘没法儿玩_老虎社区_美港股上老虎 - 老虎社区

老虎没有暗盘没法儿玩儿了

嘉和生物首日上市高开超20%，高瓴等为基石投资者

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

艾尔莎
2020-10-07
艾尔莎
就是就是，富途暗盘37.5好多人成交。

发表看法

1

1

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":300368579,"tweetId":"300368579","gmtCreate":1602033878191,"gmtModify":1703825660500,"author":{"id":24966295046426,"authorId":24966295046426,"authorIdStr":"24966295046426","name":"dafeng","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>老虎没有暗盘没法儿玩儿了</p></body></html>","htmlText":"<html><head></head><body><p>老虎没有暗盘没法儿玩儿了</p></body></html>","text":"老虎没有暗盘没法儿玩儿了","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/300368579","repostId":1191082605,"repostType":4,"repost":{"id":"1191082605","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1602033707,"share":"https://www.laohu8.com/m/news/1191082605?lang=&edition=full","pubTime":"2020-10-07 09:21","market":"us","language":"zh","title":"嘉和生物首日上市高开超20%，高瓴等为基石投资者","url":"https://stock-news.laohu8.com/highlight/detail?id=1191082605","media":"老虎资讯综合","summary":"嘉和生物(06998.HK)首日上市高开超21%，报29.2港元，发行价24港元/股；昨日暗盘收涨38.75%。公司是一家生物制药巨头，致力于开发和商业化肿瘤学和自身免疫性药物。已成功研发出靶向通路极","content":"<p>嘉和生物(06998.HK)首日上市高开超21%，报29.2港元，发行价24港元/股；昨日暗盘收涨38.75%。<img src=\"https://static.tigerbbs.com/19034542768b06e3d7e79c7bce52f397\" tg-width=\"1500\" tg-height=\"3164\">公司是一家生物制药巨头，致力于开发和商业化肿瘤学和自身免疫性药物。已成功研发出靶向通路极具潜力的候选药物，涵盖全球前三大肿瘤靶点及前十款畅销药物中的五款。</p><p>公司称预计未来12~18个月内将持续向中国药监局和FDA提交NDA及多项临床研究新药申请。公司此次IPO价格为24港元，公开发售获1247倍认购，成为今年超购倍数第五高的新股。</p><p>公司获全球顶尖机构投资者和老牌药企入股，包括高瓴资本旗下HHJH及HM Healthcare，<a href=\"https://laohu8.com/S/600572\">康恩贝</a>旗下子公司康嘉医疗及康和医疗，淡马锡旗下的Aranda Investments等。</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>嘉和生物首日上市高开超20%，高瓴等为基石投资者</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n嘉和生物首日上市高开超20%，高瓴等为基石投资者\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2020-10-07 09:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>嘉和生物(06998.HK)首日上市高开超21%，报29.2港元，发行价24港元/股；昨日暗盘收涨38.75%。<img src=\"https://static.tigerbbs.com/19034542768b06e3d7e79c7bce52f397\" tg-width=\"1500\" tg-height=\"3164\">公司是一家生物制药巨头，致力于开发和商业化肿瘤学和自身免疫性药物。已成功研发出靶向通路极具潜力的候选药物，涵盖全球前三大肿瘤靶点及前十款畅销药物中的五款。</p><p>公司称预计未来12~18个月内将持续向中国药监局和FDA提交NDA及多项临床研究新药申请。公司此次IPO价格为24港元，公开发售获1247倍认购，成为今年超购倍数第五高的新股。</p><p>公司获全球顶尖机构投资者和老牌药企入股，包括高瓴资本旗下HHJH及HM Healthcare，<a href=\"https://laohu8.com/S/600572\">康恩贝</a>旗下子公司康嘉医疗及康和医疗，淡马锡旗下的Aranda Investments等。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/f1ba9d7118bf176c3c40e42b5a99126a","relate_stocks":{},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191082605","content_text":"嘉和生物(06998.HK)首日上市高开超21%，报29.2港元，发行价24港元/股；昨日暗盘收涨38.75%。公司是一家生物制药巨头，致力于开发和商业化肿瘤学和自身免疫性药物。已成功研发出靶向通路极具潜力的候选药物，涵盖全球前三大肿瘤靶点及前十款畅销药物中的五款。公司称预计未来12~18个月内将持续向中国药监局和FDA提交NDA及多项临床研究新药申请。公司此次IPO价格为24港元，公开发售获1247倍认购，成为今年超购倍数第五高的新股。公司获全球顶尖机构投资者和老牌药企入股，包括高瓴资本旗下HHJH及HM Healthcare，康恩贝旗下子公司康嘉医疗及康和医疗，淡马锡旗下的Aranda Investments等。","news_type":1},"isVote":1,"tweetType":1,"viewCount":811,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":24,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":2917921,"gmtCreate":1602034240437,"gmtModify":1602034334711,"authorId":3555673188652701,"author":{"id":3555673188652701,"authorId":3555673188652701,"name":"艾尔莎","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":300368579,"type":1,"supId":0,"prevId":0,"content":"就是就是，富途暗盘37.5好多人成交。","text":"就是就是，富途暗盘37.5好多人成交。","html":"就是就是，富途暗盘37.5好多人成交。","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/300368579"}